Georg Fuernau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4221978/publications.pdf

Version: 2024-02-01

153 papers 11,762 citations

57758 44 h-index 28297 105 g-index

177 all docs

177
docs citations

177 times ranked

9255 citing authors

#	Article	IF	CITATIONS
1	Prognostic relevance of peri-infarct zone measured by cardiovascular magnetic resonance in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2022, 347, 83-88.	1.7	8
2	Impact of timing of intraaortic balloon counterpulsation on mortality in cardiogenic shock – a subanalysis of the IABP-SHOCK II trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 54-61.	1.0	12
3	Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial. American Heart Journal, 2021, 232, 185-193.	2.7	13
4	The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction. European Heart Journal, 2021, 42, 2344-2352.	2.2	68
5	Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis. ESC Heart Failure, 2021, 8, 953-961.	3.1	10
6	Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Myocardial and Microvascular Injury in Acute Myocardial Infarction: Insights From the Randomized MonAMI Trial. Journal of the American Heart Association, 2021, 10, e018881.	3.7	12
7	Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial. American Heart Journal, 2021, 234, 1-11.	2.7	88
8	Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. Clinical Research in Cardiology, 2021, 110, 1493-1503.	3.3	3
9	Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. New England Journal of Medicine, 2021, 385, 2544-2553.	27.0	197
10	Comparison of risk prediction models in infarct-related cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 890-897.	1.0	11
11	Reply. JACC: Cardiovascular Interventions, 2021, 14, 109-110.	2.9	O
12	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRITâ€5HOCK Substudy. Journal of the American Heart Association, 2021, 10, e021150.	3.7	1
13	Real-world clinical experience with the percutaneous extracorporeal life support system: Results from the German Lifebridge® Registry. Clinical Research in Cardiology, 2020, 109, 46-53.	3.3	10
14	Prognostic implications of microcirculatory perfusion versus macrocirculatory perfusion in cardiogenic shock: a CULPRIT-SHOCK substudy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 108-119.	1.0	25
15	Arterial Lactate in Cardiogenic Shock. JACC: Cardiovascular Interventions, 2020, 13, 2208-2216.	2.9	61
16	Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock. JAMA Cardiology, 2020, 5, 1329.	6.1	9
17	Effects of ON-Hours Versus OFF-Hours Admission on Outcome in Patients With Myocardial Infarction and Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2020, 13, e009562.	3.9	5
18	Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction. Journal of Clinical Medicine, 2020, 9, 735.	2.4	14

#	Article	IF	Citations
19	Selenoprotein P in Myocardial Infarction With Cardiogenic Shock. Shock, 2020, 53, 58-62.	2.1	8
20	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2020, 13 , e008537.	3.9	35
21	Extracorporeal life support system during cardiovascular procedures: Insights from the German Lifebridge registry. Artificial Organs, 2020, 44, 1259-1266.	1.9	2
22	Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial. Journal of Clinical Medicine, 2020, 9, 1976.	2.4	9
23	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. American Heart Journal, 2020, 225, 60-68.	2.7	16
24	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. Journal of Clinical Medicine, 2020, 9, 860.	2.4	8
25	Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock. JACC: Cardiovascular Interventions, 2020, 13, 1198-1206.	2.9	12
26	Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Ticagrelor-Induced Platelet Inhibition in Acute Myocardial Infarction. Circulation, 2020, 141, 1354-1356.	1.6	17
27	Intramyocardial haemorrhage and prognosis after ST-elevation myocardial infarction. European Heart Journal Cardiovascular Imaging, 2019, 20, 138-146.	1.2	70
28	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction. Circulation, 2019, 139, 448-457.	1.6	54
29	Response by Fuernau and Thiele to Letters Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trialâ€, Circulation, 2019, 140, e158-e159.	1.6	1
30	Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery $\hat{a} \in \hat{a}$ a sub-analysis of the RIPHeart-Study. BMC Cardiovascular Disorders, 2019, 19, 26.	1.7	18
31	Prognostic Impact of Atrial Fibrillation in Acute Myocardial Infarction and Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2019, 12, e007661.	3.9	18
32	Lactate Clearance Predicts Good Neurological Outcomes in Cardiac Arrest Patients Treated with Extracorporeal Cardiopulmonary Resuscitation. Journal of Clinical Medicine, 2019, 8, 374.	2.4	26
33	Combined Intrahospital Remote Ischemic Perconditioning and Postconditioning Improves Clinical Outcome in ST-Elevation Myocardial Infarction. Circulation Research, 2019, 124, 1482-1491.	4.5	47
34	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation, 2019, 137, 205-212.	3.0	31
35	Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury. Scientific Reports, 2019, 9, 18367.	3.3	27
36	Lactate and other biomarkers as treatment target in cardiogenic shock. Current Opinion in Critical Care, 2019, 25, 403-409.	3.2	17

#	Article	IF	CITATIONS
37	Impact of direct stenting on myocardial injury assessed by cardiac magnetic resonance imaging and prognosis in ST-elevation myocardial infarction. International Journal of Cardiology, 2019, 283, 88-92.	1.7	18
38	Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction. Circulation, 2019, 139, 395-403.	1.6	246
39	Reply to the letter to the editor "The impact of chronic total occlusion in non-infarct-related coronary arteries". EuroIntervention, 2019, 15, e299-e230.	3.2	0
40	Impact of a novel contrast reduction system on contrast savings in coronary angiography – The DyeVert randomised controlled trial. International Journal of Cardiology, 2018, 257, 50-53.	1.7	27
41	Impact of Atrial Fibrillation During ST-Segment–Elevation Myocardial Infarction on Infarct Characteristics and Prognosis. Circulation: Cardiovascular Imaging, 2018, 11, e006955.	2.6	21
42	Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shockâ€"a substudy of the IABP-SHOCK II-trial. Clinical Research in Cardiology, 2018, 107, 517-523.	3.3	17
43	RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study: Myocardial Dysfunction, Postoperative Neurocognitive Dysfunction, and 1ÂYear Followâ€Up. Journal of the American Heart Association, 2018, 7, .	3.7	28
44	Prognostic Value and Determinants of CMR-Derived Left Atrial Function Assessed in STEMI. JACC: Cardiovascular Imaging, 2018, 11, 148-150.	5.3	8
45	Prognostic Significance of Remote Myocardium Alterations Assessed by Quantitative Noncontrast T1 Mapping in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 411-419.	5.3	75
46	Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 28-37.	1.0	67
47	Prognostic impact of atrial fibrillation in cardiogenic shock complicating acute myocardial infarction: a substudy of the IABP-SHOCK II trial. Clinical Research in Cardiology, 2018, 107, 233-240.	3.3	17
48	Impact of left ventricular hypertrophy on myocardial injury in patients with ST-segment elevation myocardial infarction. Clinical Research in Cardiology, 2018, 107, 1013-1020.	3.3	17
49	Impact of Off-Hours Versus On-Hours Primary Percutaneous Coronary Intervention on Myocardial Damage and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 915-917.	2.9	7
50	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. New England Journal of Medicine, 2018, 379, 1699-1710.	27.0	303
51	Impact of chronic total occlusion in a non-infarct-related coronary artery on myocardial injury assessed by cardiac magnetic resonance imaging and prognosis in ST-elevation myocardial infarction. International Journal of Cardiology, 2018, 265, 251-255.	1.7	14
52	Prognostic impact of non-culprit chronic total occlusions in infarct-related cardiogenic shock: results of the randomised IABP-SHOCK II trial. EuroIntervention, 2018, 14, e306-e313.	3.2	20
53	Revascularization Strategies in Patients With Acute MI and Cardiogenic Shock. Journal of the American College of Cardiology, 2018, 71, 2985-2986.	2.8	0
54	Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 592-600.	1.0	16

#	Article	IF	CITATIONS
55	Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction. European Heart Journal Cardiovascular Imaging, 2017, 18, 39-45.	1.2	32
56	Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock. Heart, 2017, 103, 1177-1184.	2.9	18
57	Risk Stratification for Patients inÂCardiogenic Shock After AcuteÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2017, 69, 1913-1920.	2.8	269
58	Relationship between diabetes and ischaemic injury among patients with revascularized <scp>ST</scp> â€elevation myocardial infarction. Diabetes, Obesity and Metabolism, 2017, 19, 1706-1713.	4.4	32
59	A first in human evaluation of a novel contrast media saving device. Catheterization and Cardiovascular Interventions, 2017, 90, 928-934.	1.7	12
60	Myocardial salvage after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction presenting early versus late after symptom onset. International Journal of Cardiovascular Imaging, 2017, 33, 1571-1579.	1.5	17
61	Interventional therapies in acute myocardial infarction complicated by cardiogenic shock. Herz, 2017, 42, 11-17.	1.1	4
62	IMPACT OF TIMING OF INTRA-AORTIC BALLOON COUNTERPULSATION ON MORTALITY IN CARDIOGENIC SHOCK: A SUB-ANALYSIS OF THE IABP-SHOCK II-TRIAL. Journal of the American College of Cardiology, 2017, 69, 1182.	2.8	3
63	OUTCOME OF ELDERLY PATIENTS UNDERGOING EXTRACORPOREAL LIFE SUPPORT IN REFRACTORY CARDIOGENIC SHOCK. Journal of the American College of Cardiology, 2017, 69, 1186.	2.8	0
64	PROGNOSTIC VALUE AND DETERMINANTS OF LEFT ATRIAL FUNCTION ASSESSED BY CARDIAC MAGNETIC RESONANCE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, 2017, 69, 1445.	2.8	0
65	Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock. Clinical Research in Cardiology, 2017, 106, 341-349.	3.3	37
66	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine, 2017, 377, 2419-2432.	27.0	764
67	Optimized Prognosis Assessment in ST-Segment–Elevation Myocardial Infarction Using a Cardiac Magnetic Resonance Imaging Risk Score. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	42
68	Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal, 2017, 38, 3523-3531.	2.2	280
69	Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock. Clinical Research in Cardiology, 2017, 106, 379-385.	3.3	25
70	Catalytic iron in acute myocardial infarction complicated by cardiogenic shock — A biomarker substudy of the IABP-SHOCK II-trial. International Journal of Cardiology, 2017, 227, 83-88.	1.7	14
71	Editor's Choice- Impact of immediate multivessel percutaneous coronary intervention versus culprit lesion intervention on 1-year outcome in patients with acute myocardial infarction complicated by cardiogenic shock: Results of the randomised IABP-SHOCK II trial. European Heart Journal: Acute Cardiovascular Care. 2017, 6, 601-609.	1.0	30
72	Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clinical Research in Cardiology, 2016, 105, 1030-1041.	3.3	22

#	Article	IF	Citations
73	Shock Index as a Predictor of Myocardial Damage and Clinical Outcome in ST-Elevation Myocardial Infarction. Circulation Journal, 2016, 80, 924-930.	1.6	36
74	Smoke over myocardial infarction: cigarettes and reperfusion injury. European Heart Journal, 2016, 37, 2765-2767.	2.2	2
75	Hemodynamic Assessment of AorticÂRegurgitation After TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 1061-1068.	2.9	16
76	Impact of Initial Culprit Vessel Flow on Infarct Size, Microvascular Obstruction, and Myocardial Salvage in Acute Reperfused ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2016, 118, 1316-1322.	1.6	20
77	"Smoker's paradox―in patients with cardiogenic shock complicating myocardial infarction - A substudy of the IABP-SHOCK II-trial and registry. International Journal of Cardiology, 2016, 222, 775-779.	1.7	11
78	Deep sedation versus general anesthesia in percutaneous edge-to-edge mitral valve reconstruction using the MitraClip system. Clinical Research in Cardiology, 2016, 105, 535-543.	3.3	29
79	Thrombus Aspiration in Patients WithÂST-Segment Elevation MyocardialÂInfarction Presenting LateÂAfterÂSymptomÂOnset. JACC: Cardiovascular Interventions, 2016, 9, 113-122.	2.9	46
80	The challenges and impact of microvascular injury in ST-elevation myocardial infarction. Expert Review of Cardiovascular Therapy, 2016, 14, 431-443.	1.5	31
81	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 2016, 172, 160-169.	2.7	93
82	Incidence, determinants and prognostic relevance of cardiogenic shock in patients with Takotsubo cardiomyopathy. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 489-496.	1.0	77
83	Outcome predictors in cardiopulmonary resuscitation facilitated by extracorporeal membrane oxygenation. Clinical Research in Cardiology, 2016, 105, 196-205.	3.3	47
84	Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 80.	3.3	20
85	Long-term prognosis after extracorporeal life support in refractory cardiogenic shock: results from a real-world cohort. EuroIntervention, 2016, 11, 1363-1371.	3.2	33
86	Interventional post-myocardial infarction ventricular septal defect closure: a systematic review of current evidence. EuroIntervention, 2016, 12, 94-102.	3.2	78
87	Long-term prognosis after extracorporeal life support in refractory cardiogenic shock – results from a real-world cohort. EuroIntervention, 2016, 12, 414-414.	3.2	11
88	ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis. EuroIntervention, 2016, 12, e1395-e1403.	3.2	19
89	Impairment of the Endothelial Glycocalyx in Cardiogenic Shock and its Prognostic Relevance. Shock, 2015, 43, 450-455.	2.1	40
90	Angiopoietinâ€⊋ in acute myocardial infarction complicated by cardiogenic shock—a biomarker substudy of the <scp>IABPâ€SHOCK II</scp> â€Trial. European Journal of Heart Failure, 2015, 17, 1152-1160.	7.1	46

#	Article	IF	Citations
91	Gender differences in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clinical Research in Cardiology, 2015, 104, 71-78.	3.3	58
92	Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy. Clinical Research in Cardiology, 2015, 104, 679-687.	3.3	52
93	Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. American Heart Journal, 2015, 169, e7-e8.	2.7	14
94	Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clinical Research in Cardiology, 2015, 104, 727-734.	3.3	63
95	Impact of oxidative stress on myocardial damage visualized by cardiac resonance imaging in acute ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P99.	3.3	0
96	Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction - insights from cardiac magnetic resonance imaging. Journal of Cardiovascular Magnetic Resonance, 2015, 17, .	3.3	1
97	Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial. International Journal of Cardiology, 2015, 191, 159-166.	1.7	46
98	A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. New England Journal of Medicine, 2015, 373, 1397-1407.	27.0	515
99	Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. European Heart Journal, 2015, 36, 3049-3057.	2.2	190
100	Comparison of Sirolimus-Eluting Stenting With Minimally Invasive Bypass Surgery for Stenosis of the Left Anterior Descending Coronary Artery. JACC: Cardiovascular Interventions, 2015, 8, 30-38.	2.9	72
101	Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clinical Research in Cardiology, 2015, 104, 380-387.	3.3	37
102	Incidence, characteristics and functional implications of cerebral embolic lesions after the MitraClip procedure. EuroIntervention, 2015, 10, 1195-1203.	3.2	25
103	Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Critical Care, 2014, 18, 713.	5.8	38
104	Growthâ€differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the ⟨scp⟩IABPâ€SHOCK II⟨/scp⟩â€trial. European Journal of Heart Failure, 2014, 16, 880-887.	7.1	50
105	Outcome in Patients With Leftâ€Sided Nativeâ€Valve Infective Endocarditis and Isolated Large Vegetations. Clinical Cardiology, 2014, 37, 626-633.	1.8	18
106	Intra-aortic balloon counterpulsation — Basic principles and clinical evidence. Vascular Pharmacology, 2014, 60, 52-56.	2.1	30
107	The potential additional diagnostic value of assessing for pericardial effusion on cardiac magnetic resonance imaging in patients with suspected myocarditis. European Heart Journal Cardiovascular Imaging, 2014, 15, 643-650.	1.2	18
108	Comprehensive Prognosis Assessment by CMR Imaging After ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 64, 1217-1226.	2.8	314

#	Article	IF	CITATIONS
109	Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 110-117.	1.0	19
110	Prognosis after ST-elevation myocardial infarction: a study on cardiac magnetic resonance imaging versus clinical routine. Trials, 2014, 15, 249.	1.6	43
111	Reprint of "Intra-aortic balloon counterpulsation — Basic principles and clinical evidenceâ€. Vascular Pharmacology, 2014, 61, 30-34.	2.1	3
112	Impact of Long-Term Statin Pretreatment on Myocardial Damage in ST Elevation Myocardial Infarction (from the AIDA STEMI CMR Substudy). American Journal of Cardiology, 2014, 114, 503-509.	1.6	11
113	Prognostic significance of papillary muscle infarction detected by late gadolinium-enhanced MRI in acute reperfused ST-segment elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2013, 15, .	3.3	0
114	OSTEOPROTEGERIN IN ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK: A BIOMARKER SUBSTUDY OF THE IABP-SHOCK II-TRIAL. Journal of the American College of Cardiology, 2013, 61, E21.	2.8	0
115	Comparison of Bare-Metal Stenting With Minimally Invasive Bypass Surgery for Stenosis of the Left Anterior Descending Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 20-26.	2.9	60
116	Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet, The, 2013, 382, 1638-1645.	13.7	771
117	Osteoprotegerin in ST-elevation myocardial infarction: Prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. International Journal of Cardiology, 2013, 167, 2134-2139.	1.7	27
118	Intra-Aortic Balloon Pump (IABP) in cardiogenic shock. Current Opinion in Critical Care, 2013, 19, 404-409.	3.2	6
119	The spectrum of haemodynamic support in cardiogenic shock: how to choose and use. Kardiologia Polska, 2013, 71, 887-892.	0.6	2
120	Sex Differences in Myocardial Salvage and Clinical Outcome in Patients With Acute Reperfused ST-Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2012, 5, 119-126.	2.6	38
121	Prognostic Impact of Hyperglycemia in Nondiabetic and Diabetic Patients With ST-Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2012, 5, 708-718.	2.6	74
122	Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. American Heart Journal, 2012, 164, 706-714.	2.7	120
123	CIRCULATING MICRO-RNA 133A AS PREDICTOR OF MYOCARDIAL SALVAGE AND CLINICAL PROGNOSIS IN PATIENTS WITH ACUTE REPERFUSED ST-ELEVATION MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, 2012, 59, E1083.	2.8	0
124	Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock. New England Journal of Medicine, 2012, 367, 1287-1296.	27.0	2,574
125	Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. American Heart Journal, 2012, 163, 938-945.	2.7	135
126	The Leipzig Prospective Vascular Ultrasound Registry in Radial Artery Catheterization. JACC: Cardiovascular Interventions, 2012, 5, 36-43.	2.9	232

#	Article	IF	Citations
127	Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected Myocarditis. JACC: Cardiovascular Imaging, 2012, 5, 513-524.	5.3	239
128	What is the evidence for IABP in STEMI with and without cardiogenic shock?. Therapeutic Advances in Cardiovascular Disease, 2012, 6, 123-132.	2.1	18
129	Impact of chronic statin-pretreatment on myocardial damage as assessed by Cardiac Magnetic Resonance findings in patients with acute ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2012, 14, .	3.3	0
130	Reliability of myocardial salvage assessment by cardiac magnetic resonance imaging in acute reperfused myocardial infarction. International Journal of Cardiovascular Imaging, 2012, 28, 263-272.	1.5	49
131	Relationship and prognostic value of microvascular obstruction and infarct size in ST-elevation myocardial infarction as visualized by magnetic resonance imaging. Clinical Research in Cardiology, 2012, 101, 487-495.	3.3	58
132	Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Clinical Research in Cardiology, 2012, 101, 117-124.	3.3	42
133	Time-dependency, predictors and clinical impact of infarct transmurality assessed by magnetic resonance imaging in patients with ST-elevation myocardial infarction reperfused by primary coronary percutaneous intervention. Clinical Research in Cardiology, 2012, 101, 191-200.	3.3	17
134	Myocardium at Risk in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2011, 4, 967-976.	5. 3	53
135	Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. International Journal of Cardiology, 2011, 153, 21-25.	1.7	12
136	Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. Clinical Research in Cardiology, 2011, 100, 425-432.	3.3	23
137	Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clinical Research in Cardiology, 2011, 100, 1037-1043.	3.3	30
138	Measuring Treatment Effects in Clinical Trials Using Cardiac MRI. Current Cardiovascular Imaging Reports, 2011, 4, 98-107.	0.6	4
139	Gender differences in myocardial salvage and clinical outcome in patients with acute reperfused ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2011, 13, .	3.3	0
140	Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2011, 13, .	3.3	0
141	Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction. Trials, 2011, 12, 204.	1.6	49
142	Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart, 2011, 97, 2038-2045.	2.9	89
143	Tools & EuroIntervention, 2011, 7, 636-637.	3.2	1
144	Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	1

#	Article	IF	CITATIONS
145	Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. European Heart Journal, 2010, 31, 2660-2668.	2.2	204
146	Impact of High-Dose N-Acetylcysteine Versus Placebo on Contrast-Induced Nephropathy and Myocardial Reperfusion Injury in Unselected Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 55, 2201-2209.	2.8	191
147	Prognostic Significance and Determinants of Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance in Acute Reperfused Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 2470-2479.	2.8	406
148	Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. American Heart Journal, 2010, 159, 882-890.	2.7	65
149	Effect of Coronary Collaterals on Microvascular Obstruction as Assessed by Magnetic Resonance Imaging in Patients With Acute ST-Elevation Myocardial Infarction Treated by Primary Coronary Intervention. American Journal of Cardiology, 2009, 104, 1204-1209.	1.6	35
150	Prognostic significance and magnetic resonance imaging findings in aborted myocardial infarction after primary angioplasty. American Heart Journal, 2009, 158, 806-813.	2.7	33
151	Delayed enhancement magnetic resonance imaging in isolated noncompaction of ventricular myocardium. Clinical Research in Cardiology, 2008, 97, 277-279.	3.3	20
152	Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2008, 118, 49-57.	1.6	286
153	Clinical Applications of Cardiovascular Magnetic Resonance. Current Pharmaceutical Design, 2005, 11, 457-475.	1.9	16